Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ...

We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management. In this article, we are going ...

Signaturefd LLC lifted its holdings in Repligen Co. (NASDAQ:RGEN – Free Report) by 172.2% in the 4th quarter, according to ...

Repligen’s strong growth and bioprocessing expansion position it for success. Find out why RGEN stock is a Buy, with a $175 ...

Learn more about whether Medpace Holdings, Inc. or Repligen Corporation is a better investment based on AAII's A+ Investor ...

This quarter, Repligen’s $167.5 million of revenue was flat year on year and in line with Wall Street’s estimates. Looking ahead, sell-side analysts expect revenue to grow 9% over the next 12 ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Evercore ISI initiated coverage of Repligen (RGEN) with an In Line rating and $155 price target The firm sees the company as a high quality ...

Repligen has acquired 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology applications for $70 million in cash. Repligen, a Waltham, Mass., life-sciences ...

WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc ...

Repligen Corporation RGEN reported fourth-quarter 2024 adjusted earnings per share of 44 cents, which beat the Zacks Consensus Estimate of 41 cents. The company had recorded adjusted earnings of ...

In this article, we are going to take a look at where Repligen Corporation (NASDAQ:RGEN) stands against other top stocks to buy according to 12 West Capital Management. Joel Ramin founded 12 West ...